Hydrocl: Advanced Diuretic Therapy for Edema Management
Hydrocl
| Product dosage: 12.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.39 | $47.00 (0%) | 🛒 Add to cart |
| 180 | $0.36 | $70.50 $65.00 (8%) | 🛒 Add to cart |
| 270 | $0.33 | $105.75 $89.00 (16%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $141.00 $108.00 (23%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.49 | $44.00 (0%) | 🛒 Add to cart |
| 120 | $0.46 | $58.67 $55.00 (6%) | 🛒 Add to cart |
| 180 | $0.42 | $88.00 $75.00 (15%) | 🛒 Add to cart |
| 270 | $0.40 | $132.00 $107.00 (19%) | 🛒 Add to cart |
| 360 | $0.39
Best per pill | $176.00 $139.00 (21%) | 🛒 Add to cart |
Hydrocl (hydrochlorothiazide) is a thiazide diuretic indicated for the management of edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid or estrogen therapy. It is also prescribed for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. This medication works by inhibiting sodium reabsorption in the distal convoluted tubule, promoting the excretion of sodium and water, thereby reducing fluid retention and lowering blood pressure. Hydrocl is a cornerstone in therapeutic regimens for cardiovascular and renal conditions, valued for its predictable pharmacokinetics and well-established efficacy profile.
Features
- Contains hydrochlorothiazide as the active pharmaceutical ingredient
- Available in 12.5 mg, 25 mg, and 50 mg oral tablets
- Rapid onset of action, with diuretic effects observed within 2 hours of administration
- Peak plasma concentration reached within 4 hours post-dose
- Elimination half-life of approximately 5.6–14.8 hours
- Excreted primarily unchanged in urine
- Manufactured under cGMP conditions for consistent quality and potency
Benefits
- Effectively reduces edema and fluid overload in cardiac, hepatic, and renal conditions
- Lowers blood pressure through reduction in plasma volume and peripheral vascular resistance
- May reduce the risk of stroke, myocardial infarction, and heart failure in hypertensive patients
- Compatible with many other cardiovascular medications for combination therapy
- Well-tolerated profile with extensive clinical experience spanning decades
- Cost-effective therapeutic option with multiple generic formulations available
Common use
Hydrocl is commonly prescribed for the treatment of edema secondary to congestive heart failure, cirrhosis of the liver, and nephrotic syndrome. It is also widely used as an antihypertensive agent, either as initial monotherapy or as part of a combination regimen with other antihypertensive drugs such as ACE inhibitors, angiotensin receptor blockers, or beta-blockers. In some cases, it may be used off-label for the prevention of calcium-containing kidney stones in hypercalciuric patients or for the treatment of diabetes insipidus.
Dosage and direction
The dosage of Hydrocl must be individualized based on patient response and therapeutic goals. For edema: initial dose is 25–100 mg daily as a single or divided dose. For hypertension: initial dose is 12.5–25 mg once daily. Maintenance doses may range from 12.5–50 mg daily. The dosage may be titrated upward at intervals of 2–4 weeks based on blood pressure response. Administer with or without food, preferably in the morning to avoid nocturia. Dosage adjustment is required in patients with renal impairment (CrCl <30 mL/min not recommended).
Precautions
Monitor blood pressure, electrolyte levels (particularly potassium, sodium, and magnesium), renal function, and blood glucose regularly during therapy. Use with caution in patients with impaired hepatic function or progressive liver disease, as minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Avoid in patients with history of hypersensitivity to sulfonamide-derived drugs. Photosensitivity reactions may occur; advise patients to use sun protection. Orthostatic hypotension may occur, especially in elderly patients or those volume-depleted.
Contraindications
Hydrocl is contraindicated in patients with anuria, history of hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs, and in patients with refractory hypokalemia. It should not be used during breastfeeding due to secretion in human milk. Concurrent use with lithium is contraindicated due to increased risk of lithium toxicity.
Possible side effect
Common adverse reactions include hypokalemia (3.5–8.0%), hyperuricemia (5–10%), hyperglycemia (2–5%), and orthostatic hypotension (2–4%). Less frequently reported effects include photosensitivity, rash, nausea, dizziness, and headache. Rare but serious side effects may include pancreatitis, jaundice, leukopenia, agranulocytosis, aplastic anemia, and anaphylactic reactions. Electrolyte imbalances may manifest as muscle cramps, weakness, or cardiac arrhythmias.
Drug interaction
Hydrocl may potentiate the effects of other antihypertensive agents. Concurrent use with corticosteroids, amphotericin B, or corticotropin may increase potassium depletion. It may decrease renal clearance of lithium and increase lithium toxicity risk. Thiazides may reduce the effect of oral anticoagulants. NSAIDs may reduce the diuretic and antihypertensive effects of Hydrocl. Cholestyramine and colestipol may reduce absorption of hydrochlorothiazide.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed dose. Maintain regular dosing schedule to ensure consistent therapeutic effect.
Overdose
Symptoms of overdose include electrolyte imbalance (hypokalemia, hyponatremia), dehydration, and circulatory collapse. Gastric lavage and supportive measures including electrolyte replacement and volume resuscitation should be instituted immediately. There is no specific antidote; treatment should be symptomatic and supportive. Hemodialysis is not effective for hydrochlorothiazide removal.
Storage
Store at controlled room temperature (20–25°C or 68–77°F). Protect from light and moisture. Keep in original container with lid tightly closed. Keep out of reach of children and pets. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Hydrocl is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for specific medical advice, diagnosis, and treatment. Never disregard professional medical advice or delay seeking it because of something you have read in this product information.
Reviews
Clinical studies have demonstrated Hydrocl’s efficacy in reducing edema and controlling hypertension. In the SHEP trial, hydrochlorothiazide-based therapy reduced stroke incidence by 36% in elderly patients with isolated systolic hypertension. The ALLHAT study confirmed its effectiveness as first-line antihypertensive therapy. Many clinicians report satisfactory patient outcomes with good tolerability, though monitoring for metabolic side effects remains essential. Patient satisfaction surveys indicate generally positive experiences when electrolyte imbalances are properly managed.